Non-small cell lung cancer (NSCLC) Clinical Trials in Boston, MA

As of August 2026, 65 paid clinical trials are recruiting for Non-small cell lung cancer (NSCLC) in Boston, Massachusetts. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: August 31, 2026.

Related specialties in Boston

Oncology· 1,141 Lung oncology· 108

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

65 clinical trials for Non-small cell lung cancer (NSCLC)

·Clear filters·

Email me when a new non-small cell lung cancer (nsclc) trial opens in Boston, MA.

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

for Solid Tumor, Adult

Sites in Boston +12 more locations

Sponsor: GV20 Therapeutics

Sex: All·Age: 18+

Code: NCT05669430·Phase 1, Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

for Non-small Cell Lung Cancer (NSCLC)

Sites in Boston +8 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT07349537·Phase 1·Recruiting·Listed Jan 2026

Apply to this trial

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

for Colorectal Cancer

Sites in Boston +4 more locations

Sponsor: PAQ Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07300150·Phase 1·Recruiting·Listed Dec 2025

Apply to this trial

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

Sites in Boston +10 more locations

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT07111520·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

for Non Small Cell Lung Cancer

Sites in Boston +8 more locations

Sponsor: Compass Therapeutics

Sex: All·Age: 18+

Code: NCT06150664·Phase 1·Recruiting·Listed Nov 2023

Apply to this trial

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

for Pancreatic Ductal Adenocarcinoma

Sites in Boston +8 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT06562192·Phase 1·Recruiting·Listed Aug 2024

Apply to this trial

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

for Biliary Tract Cancer

Sites in Boston +5 more locations

Sponsor: ModeX Therapeutics, An OPKO Health Company

Sex: All·Age: 18+

Code: NCT06239194·Phase 1, Phase 2·Recruiting·Listed Feb 2024

Apply to this trial

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

for Non Small Cell Lung Cancer

Sites in Boston +2 more locations

Sponsor: Zumutor Biologics Inc.

Sex: All·Age: 18+

Code: NCT06451497·Phase 1·Recruiting·Listed Jun 2024

Apply to this trial

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

for Solid Tumor, Adult

Sites in Boston +8 more locations

Sponsor: Vivace Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT04665206·Phase 1, Phase 2·Recruiting·Listed Dec 2020

Apply to this trial

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

for Advanced Solid Tumor

Sites in Boston +3 more locations

Sponsor: Ankyra Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06171750·Phase 1·Recruiting·Listed Dec 2023

Apply to this trial

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

for Solid Tumor

Sites in Boston +4 more locations

Sponsor: ImmVira Pharma Co. Ltd

Sex: All·Age: 18+

Code: NCT04370587·Phase 1, Phase 2·Recruiting·Listed May 2020

Apply to this trial

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

for Cancer

Sites in Boston +5 more locations

Sponsor: Simcha IL-18, Inc.

Sex: All·Age: 18+

Code: NCT04787042·Phase 1, Phase 2·Recruiting·Listed Mar 2021

Apply to this trial

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

Sites in Boston, Brighton +623 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting·Listed Feb 2020

Apply to this trial

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

for Non-small Cell Lung Cancer

Sites in Boston +19 more locations

Sponsor: Institut de Recherches Internationales Servier

Sex: All·Age: 18+

Code: NCT05786924·Phase 1, Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

for Non Small Cell Lung Cancer

Drug: Osimertinib

Sites in Boston, Stoneham +144 more locations

Sponsor: PrECOG, LLC.

Sex: All·Age: 18+

Code: NCT06538038·Recruiting·Listed Aug 2024

Apply to this trial

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

for Non-small Cell Lung Cancer

2 locations in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT04789486·Phase 1, Phase 2·Recruiting·Listed Mar 2021

Apply to this trial

Biology of Young Lung Cancer Study: The YOUNG LUNG Study

for Non Small Cell Lung Cancer

4 locations in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 15+

Code: NCT05265429·Recruiting·Listed Mar 2022

Apply to this trial

Patient-centered, Optimal Integration of Survivorship and Palliative Care

for Stage IV Non-small Cell Lung Cancer

1 location in Boston

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+

Code: NCT04900935·Recruiting·Listed May 2021

Apply to this trial

Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study

for Stage II Lung Cancer

1 location in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT07412041·Recruiting·Listed Feb 2026

Apply to this trial

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

for Non-small Cell Lung Cancer (NSCLC)

Sites in Boston +47 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07291037·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

for HNSCC

Sites in Boston +17 more locations

Sponsor: Normunity AccelCo, Inc.

Sex: All·Age: 18+

Code: NCT07182149·Phase 1·Recruiting·Listed Sep 2025

Apply to this trial

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

for Non-small Cell Lung Cancer

Sites in Boston +17 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06218914·Phase 1·Recruiting·Listed Jan 2024

Apply to this trial

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

Sites in Boston +18 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18 - 95

Code: NCT05061550·Phase 2·Recruiting·Listed Sep 2021

Apply to this trial

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

for Non-Small Cell Lung Cancer

Drug: Rilvegostomig

Sites in Boston +48 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06357533·Phase 3·Recruiting·Listed Apr 2024

Apply to this trial

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

for Non-small Cell Lung Cancer

Sites in Boston +13 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT05877599·Phase 1·Recruiting·Listed May 2023

Apply to this trial